Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytoDyn Inc.CYDY · Entity 5856 | GC and Corporate Secretary | October 23, 2020 | October 26, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytoDyn Inc.
Report date October 23, 2020 · Filed October 26, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 80,000 |
Reported balance
After 2020-10-23 transaction · row 1
1 source rowRow 1 · 2020-10-23 · Purchase · Acquired 10,000 · Balance 80,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 23, 2020 Filed Oct 26, 2020 23:54 UTC | CytoDyn Inc. CYDY · Entity 5856 | PurchaseCommon Stock | 10,000 | $2.50 | $25,000.00 |
DisclosureSEC source: 0001807094-20-000025 · primary_doc.xml · nonDerivative · entry 1 Colachis Arian · CIK 0001807094 · GC and Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Read SEC document |
| September 30, 2020 Filed Oct 3, 2020 00:41 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified Stock Option · Derivative | 150,000 | $0.00 Strike: $3.12 | $0.00 |
DisclosureSEC source: 0001807094-20-000021 · primary_doc.xml · derivative · entry 2 Colachis Arian · CIK 0001807094 · GC and Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-06-15 F3 · date: The option grant was approved by a committee of the Issuer's Board of Directors on June 15, 2020, subject to stockholder approval of the Issuer's Amended & Restated 2012 Equity Incentive Plan (the "Plan") under which the option was granted. The Issuer's stockholders approved the Plan on September 30, 2020. F4 · derivative.exercise_date: The stock option vests annually in three equal installments beginning June 15, 2021. Read SEC document |
| September 30, 2020 Filed Oct 3, 2020 00:41 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 70,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001807094-20-000021 · primary_doc.xml · nonDerivative · entry 1 Colachis Arian · CIK 0001807094 · GC and Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Amended & Restated 2012 Equity Incentive Plan. F2 · price: Not applicable. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 19:29 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001807094-20-000002 · primary_doc.xml · derivative · entry 1 Colachis Arian · CIK 0001807094 · GC and Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-03-16 F1 · derivative.exercise_date: The options will vest in three equal installments over a three-year period beginning March 16, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.